[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 121
Citations 0
Lab Reports
June 6, 2012

COX-2 Inhibitors and Heart Risks

JAMA. 2012;307(21):2247. doi:10.1001/jama.2012.5731

For years, nonsteroidal anti-inflammatory drugs that target the cyclooxygenase 2 (COX-2) enzyme have been linked to increased cardiovascular risks. New research indicates that these elevated risks occur because COX-2 inhibitors suppress prostacyclin—a vasodilator and platelet inhibitor with heart-protecting properties—in vascular cells (Yu Y et al. Sci Transl Med. 2012;4[132]:132ra54).

A team led by researchers in Pennsylvania confirmed that COX-2 is expressed in cells lining blood vessels and revealed that selectively removing it from the mouse vasculature reduced urinary excretion of the major metabolite of prostacyclin. This predisposed mice to thrombosis and hypertension. Urinary excretion of the metabolite varied inversely with blood pressure across all mutant mice.

First Page Preview View Large
First page PDF preview
First page PDF preview